IN2014MN01571A - - Google Patents

Info

Publication number
IN2014MN01571A
IN2014MN01571A IN1571MUN2014A IN2014MN01571A IN 2014MN01571 A IN2014MN01571 A IN 2014MN01571A IN 1571MUN2014 A IN1571MUN2014 A IN 1571MUN2014A IN 2014MN01571 A IN2014MN01571 A IN 2014MN01571A
Authority
IN
India
Prior art keywords
ocular
steroid
pharmaceutical composition
composition
umol
Prior art date
Application number
Other languages
English (en)
Inventor
Keelung Hong
Luke S S Guo
Sheue Fang Shih
Po Chun Chang
Chih Chiang Tsai
hong hui Lin
Yun Long Tseng
Original Assignee
Taiwan Liposome Co Ltd
Tlc Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, Tlc Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd
Publication of IN2014MN01571A publication Critical patent/IN2014MN01571A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1571MUN2014 2012-02-10 2013-02-08 IN2014MN01571A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261597189P 2012-02-10 2012-02-10
PCT/US2013/025390 WO2013119988A1 (fr) 2012-02-10 2013-02-08 Compositions pharmaceutiques destinées à réduire les complications liées à un stéroïde oculaire

Publications (1)

Publication Number Publication Date
IN2014MN01571A true IN2014MN01571A (fr) 2015-05-15

Family

ID=48948063

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1571MUN2014 IN2014MN01571A (fr) 2012-02-10 2013-02-08

Country Status (18)

Country Link
US (2) US10058616B2 (fr)
EP (1) EP2797601B1 (fr)
JP (1) JP6231995B2 (fr)
KR (1) KR102060210B1 (fr)
CN (2) CN104125830B (fr)
AU (1) AU2013216861B2 (fr)
BR (1) BR112014018393B1 (fr)
CA (1) CA2862055C (fr)
CY (1) CY1120323T1 (fr)
DK (1) DK2797601T3 (fr)
ES (1) ES2673330T3 (fr)
IN (1) IN2014MN01571A (fr)
NZ (1) NZ628124A (fr)
PT (1) PT2797601T (fr)
RU (1) RU2660585C2 (fr)
TR (1) TR201808592T4 (fr)
TW (1) TWI620578B (fr)
WO (1) WO2013119988A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111415822A (zh) * 2020-03-05 2020-07-14 沈阳农业大学 一种洋葱碳/二氧化锰阵列电极及其制备方法和应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913375YA (en) * 2016-04-19 2020-02-27 Univ Nanyang Tech Subconjuctival depot forming formulations for ocular drug delivery
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
AU2018372185B2 (en) 2017-11-21 2024-05-16 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
WO2020014118A1 (fr) * 2018-07-09 2020-01-16 Taiwan Liposome Co., Ltd. Méthodes pour réduire les complications d'un stéroïde intra-articulaire
EP3849522A1 (fr) 2018-09-16 2021-07-21 TLC Biopharmaceuticals, Inc. Compositions pharmaceutiques appropriées pour une administration articulaire et leur utilisation dans le traitement de la douleur articulaire
KR20210141448A (ko) 2018-12-27 2021-11-23 서피스 아프샐믹스 인코포레이티드 안구 표면 질환을 치료하기 위한 안과용 약학 조성물 및 방법
RU2716429C1 (ru) * 2019-05-29 2020-03-11 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения рецидивирующей эрозии роговицы различного генеза
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
SE9100342D0 (sv) 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
IL103907A0 (en) * 1992-11-27 1993-04-04 Pharmos Corp Ophthalmic compositions
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
DE602004029010D1 (de) 2003-02-04 2010-10-21 Bracco Suisse Sa Ultraschall kontrastmittel und verfahren zur erstellung
PL1768657T3 (pl) * 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US20070280902A1 (en) * 2006-06-01 2007-12-06 Laura Rabinovich-Guilatt Method for treating eye disease or conditions affecting the posterior segment of the eye
WO2007150046A2 (fr) * 2006-06-22 2007-12-27 Sirion Therapeutics, Inc Procédés et compositions pour traiter des conditions ophtalmiques par la modulation de l'activité de mégaline
US20080118500A1 (en) * 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
WO2009107753A1 (fr) * 2008-02-29 2009-09-03 財団法人 名古屋産業科学研究所 Liposome pour une administration au segment postérieur de l'œil et composition pharmaceutique pour une maladie du segment postérieur de l'œil
CN101502485A (zh) * 2009-03-20 2009-08-12 中国药科大学 地塞米松眼用纳米立方液晶制剂及其制备方法
CN101926769A (zh) * 2009-06-24 2010-12-29 天津金耀集团有限公司 地塞米松磷酸钠脂质体注射液
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
CN102917690B (zh) * 2010-03-19 2016-08-24 麻省理工学院 脂质囊泡组合物和使用方法
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111415822A (zh) * 2020-03-05 2020-07-14 沈阳农业大学 一种洋葱碳/二氧化锰阵列电极及其制备方法和应用

Also Published As

Publication number Publication date
BR112014018393A8 (pt) 2017-07-11
CY1120323T1 (el) 2019-07-10
CN104125830A (zh) 2014-10-29
US10350294B2 (en) 2019-07-16
KR102060210B1 (ko) 2019-12-27
CN104125830B (zh) 2018-01-16
CN107260679B (zh) 2020-07-31
CN107260679A (zh) 2017-10-20
KR20150008844A (ko) 2015-01-23
JP6231995B2 (ja) 2017-11-15
DK2797601T3 (en) 2018-06-14
WO2013119988A1 (fr) 2013-08-15
AU2013216861B2 (en) 2017-05-18
TW201338806A (zh) 2013-10-01
AU2013216861A1 (en) 2014-08-07
EP2797601B1 (fr) 2018-03-21
EP2797601A4 (fr) 2015-06-03
ES2673330T3 (es) 2018-06-21
NZ628124A (en) 2016-06-24
BR112014018393A2 (fr) 2017-06-20
RU2660585C2 (ru) 2018-07-06
US10058616B2 (en) 2018-08-28
TWI620578B (zh) 2018-04-11
BR112014018393B1 (pt) 2020-09-15
TR201808592T4 (tr) 2018-07-23
US20180193461A1 (en) 2018-07-12
CA2862055A1 (fr) 2013-08-15
HK1201723A1 (en) 2015-09-11
US20150011520A1 (en) 2015-01-08
EP2797601A1 (fr) 2014-11-05
RU2014132553A (ru) 2016-02-27
CA2862055C (fr) 2020-03-10
JP2015506983A (ja) 2015-03-05
PT2797601T (pt) 2018-06-27

Similar Documents

Publication Publication Date Title
IN2014MN01571A (fr)
WO2012021107A8 (fr) Formulation de liposomes pour l'administration d'un médicament dans l'oeil
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
DOP2012000225A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
AR091006A1 (es) Formulaciones de testosterona proliposomal
BR112015022476A2 (pt) composições de oxaliplatina de lipossoma para terapia de câncer
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
EA201400392A1 (ru) ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb
IN2014DN00277A (fr)
MX2015012201A (es) Formulaciones modificadas de liposomas de docetaxel.
CO6771446A2 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
WO2008070463A3 (fr) Procédés et compositions d'endoxifène
PH12014500510A1 (en) Use of omega fatty acids for treating disease
MX2014011946A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
BR112015022415A2 (pt) composições de cisplatina lipossômica para terapia contra câncer
BR112014015333A2 (pt) composições lipossomais de clorito ou clorato
CA2854430C (fr) Corticosteroides liposomaux pour le traitement des affections inflammatoires chez l'homme
NZ702705A (en) Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease
PH12015501407A1 (en) Topical opthalmological pharmaceutical composition containing regorafenib
BR112014004732A2 (pt) composto benzotiazolona
WO2011143271A3 (fr) Liposomes thérapeutiques et leurs procédés de production et d'utilisation
MX2009009171A (es) Administracion de acido 3,5-diyodotiropropionico para estimular perdida de peso y/o disminuir niveles de trigliceridos y/o para tratar sindrome metabolico.
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
WO2014184726A3 (fr) Composés et utilisation thérapeutique de ceux-ci